Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake
Rhea-AI Filing Summary
Kynam Capital Management, LP, together with Kynam Capital Management GP, LLC and Yue Tang, reports beneficial ownership of Celldex Therapeutics, Inc. common stock. The group has shared voting and dispositive power over 5,322,908 shares, representing 6.78% of Celldex’s outstanding common stock, with no sole voting or dispositive power reported for any of the filers.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership percentage: 6.78%
Shares with shared voting power: 5,322,908 shares
Shares with shared dispositive power: 5,322,908 shares
+2 more
5 metrics
Beneficial ownership percentage
6.78%
Percent of Celldex Therapeutics common stock reported as beneficially owned
Shares with shared voting power
5,322,908 shares
Shares over which the reporting persons have shared power to vote or direct the vote
Shares with shared dispositive power
5,322,908 shares
Shares over which the reporting persons have shared power to dispose or direct disposition
Par value of common stock
$0.001
Par value per share of Celldex Therapeutics common stock
CUSIP
15117B202
CUSIP number for Celldex Therapeutics common stock
Key Terms
beneficially owned, shared voting power, shared dispositive power, percent of class
4 terms
beneficially owned financial
"Item 4. | Ownership (a) | Amount beneficially owned: 0"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
percent of class financial
"Percent of class: 6.78 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
FAQ
What percentage of Celldex Therapeutics (CLDX) does Kynam Capital report owning?
Kynam Capital and related reporting persons report beneficial ownership of 6.78% of Celldex Therapeutics’ common stock, based on shared voting and dispositive power over 5,322,908 shares as described in the ownership section.
Who are the reporting persons in this Celldex (CLDX) ownership filing?
The reporting persons are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. Each reports shared voting and dispositive power over 5,322,908 shares of Celldex common stock, with no sole voting or dispositive power.
What class of Celldex (CLDX) securities is reported as owned by Kynam Capital?
The ownership relates to Celldex Therapeutics’ Common Stock, par value $0.001, identified by CUSIP 15117B202. The reporting group has shared voting and dispositive power over 5,322,908 shares of this class.
AI-generated analysis. How Rhea-AI works. Not financial advice.